Form 4 for ERAS Erasca, Inc.
Accepted 2022-02-03 00:00:00 ET · period of report 2022-02-01 · accession 0001209191-22-007065 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-03 | 2022-02-01 | ERAS | Wei Lin | Chief Medical Off | J - Other | $11.60 | +1,562 | 314.1K | +0.5% | +$18.1K |
| D | 2022-02-03 | 2022-02-01 | ERAS | Wei Lin | Chief Medical Off | A - Grant | $0.00 | +272.1K | 272.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-01 | J | A | 1,562 | $11.60 | 314,062 | D | — | — | (F1) Includes 1,562 shares acquired under the Erasca, Inc. employee stock purchase plan on December 15, 2021. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-02-01 | A | A | 272,100 | $0.00 | 272,100 | D | $11.54 · — to 2032-01-31 | 272,100 Common Stock | (F2) 1/48th of the shares subject to the option vest monthly following February 2, 2022, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |